As part of their strategic plans for growth and to meet the evolving needs of modern product developers, the Contract Research Organisation Sequani has made a significant investment in a new custom designed facility incorporating 820m2 of laboratory space and a 910m2 modern vivarium, whilst also appointing Lee Coney as CSO.
With over 30 years’ of product development and senior managerial experience in the sector, Lee will take a leading role in working with the company’s customers to develop a wide range of pharmaceutical, crop protection and chemical products.
Speaking about the new facility, Lee said, “The new lab and vivarium will enable us to be more flexible, whilst allowing us to support the evolving needs of our customers and worldwide regulatory authorities.
“Amongst other advantages, co-locating the laboratory and animal facilities into a single building offers enhanced biosecurity for sample flows from animal unit to analytical laboratory. It’s more efficient and will allow us to deliver a superior service.”
The new facility is flexible with its capabilities, so the company could work with a wider range of novel products.
As the greater part of GLP non-clinical safety testing is performed in contract research organisations, it is critical that laboratories adapt to the changing needs of their customers.
Sequani CEO, Stephen Eckley said: “Non-clinical safety assessment used to be a prescriptive business but that’s no longer the case. We work with a wide range of organisations in the pharmaceutical, crop protection and chemical industries. It’s vital that we keep abreast of developments in the field and understand how this impacts our customers.”